In a phase I clinical trial of HER2-negative breast cancer patients with early stage disease, the combination of nintedanib with conventional paclitaxel was evaluated, indicating a more tolerable toxicity profile [34] than previously observed for other antiangiogenic TKIs when they are combined with chemotherapy [13, 14, 17–19, 22–26, 31]. This evidence concerns the gene ERBB2 and breast cancer.